Global Humira Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.

Market Analysis and Insights: Global Humira Market
In 2020, the global Humira market size was US$ 17920 million and it is expected to reach US$ 10150 million by the end of 2027, with a CAGR of -8.3% during 2021-2027.
Global Humira Scope and Market Size
Humira market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Humira market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Humira market is segmented into
Humira Syringe
Humira Pen

Segment by Application, the Humira market is segmented into
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Others

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape

and Humira Market Share Analysis
Humira market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Humira product introduction, recent developments, Humira sales by region, type, application and by sales channel.

The major companies include:
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim